tbuckley/cabot-search huggingface dataset:
Gut virome and microbiome dynamics before and after SARS-CoV-2 infection in women living with HIV and their infants
Authors: Rabia Maqsood, LaRinda A. Holland, Lily I. Wu, Emily R. Begnel, Judith Adhiambo, Prestone Owiti, Bhavna H. Chohan, Soren Gantt, John Kinuthia, Dalton Wamalwa, Ednah Ojee, Barbra A. Richardson, Jennifer Slyker, Dara A. Lehman, Efrem S. Lim
Journal: Gut Microbes (2024)

Microbiome perturbations can have long-term effects on health. The dynamics of the gut microbiome and virome in women living with HIV (WLHIV) and their newborn infants is poorly understood. Here, we performed metagenomic sequencing analyses on longitudinal stool samples including 23 mothers (13 WLHIV, 10 HIV-negative) and 12 infants that experienced SARS-CoV-2 infection with mild disease, as well as 40 mothers (18 WLHIV, 22 HIV-negative) and 60 infants that remained SARS-CoV-2 seronegative throughout the study follow-up. Regardless of HIV or SARS-CoV-2 status, maternal bacterial and viral profiles were distinct from infants. Using linear mixed effects models, we showed that the microbiome alpha diversity trajectory was not significantly different between SARS-CoV-2 seropositive and seronegative women. However, seropositive women's positive trajectory while uninfected was abruptly reversed after SARS-CoV-2 infection (p = 0.015). Gut virome signatures of women were not associated with SARS-CoV-2. Alterations in infant microbiome and virome diversities were generally not impacted by SARS-CoV-2 but were rather driven by development. We did not find statistically significant interactions between HIV and SARS-CoV-2 on the gut microbiome and virome. Overall, our study provides insights into the complex interplay between maternal and infant bacterial microbiome, virome, and the influence of SARS-CoV-2 and HIV status.
Comparison of different tracers in sentinel lymph node detection for endometrial cancer: A systematic review and network meta-analysis
Authors: Chuanli Feng, Xuji Jiang, Lianlian Feng, Wanying Sun, Qingqing Liu, Yiping Hao, Baoxia Cui
Journal: International Journal of Surgery (2024)

In the realm of endometrial cancer (EC) therapeutics and prognostic assessments, lymph nodes' status is paramount. The sentinel lymph node (SLN) detection, recognized for its reliability, has been progressively adopted as a standard procedure, posing a compelling alternative to conventional systematic lymphadenectomy. However, there remains a lack of agreement on the most effective choice of tracers for this procedure.
Continuous Rhythm Monitoring With Implanted Loop Recorders in Children and Adolescents With Brugada Syndrome
Authors: Marco Bergonti, Giuseppe Ciconte, Jose Cruzalegui Gomez, Lia Crotti, Elena Arbelo, Michela Casella, Johan Saenen, Andrea Rossi, Luigi Pannone, Estefania Martinez-Barrios, Paolo Compagnucci, Vincenzo Russo, Paola Berne, Olivier Van Leuven, Antonio Boccellino, Lorenzo Marcon, Federica Dagradi, Federico Landra, Tardu Özkartal, Angelo Comune, Sergio Conti, Valentina Ribatti, Oscar Campuzano, Pedro Brugada, Carlo de Asmundis, Josep Brugada, Carlo Pappone, Claudio Tondo, Peter J Schwartz, Angelo Auricchio, Georgia Sarquella-Brugada, Giulio Conte
Journal: Journal of the American College of Cardiology (2024)

Young (<18 years of age) patients with Brugada syndrome (BrS) are often under-represented in BrS studies and their management, especially related to syncopal episodes, remains unclear.
ATLAS: A positive, high-yield review of patient symptoms most significantly associated with melanoma recurrence
Authors: Emily Everdell, Jenna Borok, Alana Deutsch, Ziyou Ren, Justine V Cohen, Gabriel Molina, Sitaram Vangala, Danica McDaniel, Hensin Tsao
Journal: Journal of the American Academy of Dermatology (2024)

No standardized, evidence-based surveillance practices exist to guide and optimize recurrence detection in patients with cutaneous melanoma.
Dissolvable microneedle-based wound dressing transdermally and continuously delivers anti-inflammatory and pro-angiogenic exosomes for diabetic wound treatment
Authors: Yanpeng Cao, Bei Chen, Qixing Liu, Yiyang Mao, Yusheng He, Xiaoren Liu, Xin Zhao, Yaowu Chen, Xiying Li, Yabei Li, Liang Liu, Chengwu Guo, Shiyu Liu, Fenghua Tan, Hongbin Lu, Jun Liu, Can Chen
Journal: Bioactive Materials (2024)

Due to overactive inflammation and hindered angiogenesis, self-healing of diabetic wounds (DW) remains challenging in the clinic. Platelet-derived exosomes (PLT-Exos), a novel exosome capable of anti-inflammation and pro-angiogenesis, show great potential in DW treatment. However, previous administration of exosomes into skin wounds is topical daub or intradermal injection, which cannot intradermally deliver PLT-Exos into the dermis layer, thus impeding its long-term efficacy in anti-inflammation and pro-angiogenesis. Herein, a dissolvable microneedle-based wound dressing (PLT-Exos@ADMMA-MN) was developed for transdermal and long-term delivery of PLT-Exos. Firstly, a photo-crosslinking methacrylated acellular dermal matrix-based hydrogel (ADMMA-GEL), showing physiochemical tailorability, fast-gelling performance, excellent biocompatibility, and pro-angiogenic capacities, was synthesized as a base material of our dressing. For endowing the dressing with anti-inflammation and pro-angiogenesis, PLT-Exos were encapsulated into ADMMA-GEL with a minimum effective concentration determined by our in-vitro experiments. Then, in-vitro results show that this dressing exhibits excellent properties in anti-inflammation and pro-angiogenesis. Lastly, in-vivo experiments showed that this dressing could continuously and transdermally deliver PLT-Exos into skin wounds to switch local macrophage into M2 phenotype while stimulating neovascularization, thus proving a low-inflammatory and pro-angiogenic microenvironment for DW healing. Collectively, this study provides a novel wound dressing capable of suppressing inflammation and stimulating vascularization for DW treatment.
Tricuspid Regurgitation and Heart Failure: the Fate of Treated vs Untreated Cohort in the Percutaneous Era
Authors: Edoardo Zancanaro, Maria Rita Romeo, Annalisa Nardone, Andreina D’Agostino, Massimiliano Mariani, Sergio Berti
Journal:  (2024)

Tricuspid regurgitation (TR) is associated with heart failure (HF) and reduced survival. Within a short-time period, transcatheter tricuspid valve repair or replacement (TTVR/TTVr) for TR has evolved from innovation to clinical reality. The present study's aim is to provide 1-year results between TR patients treated with TTVR and TTVr compared with untreated patients, in terms of cardiac survival, rehospitalization, right-side HF symptom development, and New York Heart Association (NYHA) improvement.
Real-world effectiveness and tolerability of switching to doravirine-based antiretroviral therapy in people with HIV: a nationwide, matched, prospective cohort study
Authors: Patrick G A Oomen, Ferdinand W N M Wit, Kees Brinkman, Saskia M E Vrouenraets, Tania Mudrikova, Berend J van Welzen, Marc van der Valk
Journal: The Lancet HIV (2024)
Clinical research in endometrial cancer: consensus recommendations from the Gynecologic Cancer InterGroup
Authors: Carien L Creutzberg, Jae-Weon Kim, Gemma Eminowicz, Emma Allanson, Lauriane Eberst, Se Ik Kim, Remi A Nout, Jeong-Yeol Park, Domenica Lorusso, Linda Mileshkin, Petronella B Ottevanger, Alison Brand, Delia Mezzanzanica, Amit Oza, Val Gebski, Bhavana Pothuri, Tania Batley, Carol Gordon, Tina Mitra, Helen White, Brooke Howitt, Xavier Matias-Guiu, Isabelle Ray-Coquard, David Gaffney, William Small, Austin Miller, Nicole Concin, Matthew A Powell, Gavin Stuart, Michael A Bookman
Journal: The Lancet Oncology (2024)
The oncological role of resection in newly diagnosed diffuse adult-type glioma defined by the WHO 2021 classification: a Review by the RANO resect group
Authors: Philipp Karschnia, Jasper K W Gerritsen, Nico Teske, Daniel P Cahill, Asgeir S Jakola, Martin van den Bent, Michael Weller, Oliver Schnell, Einar O Vik-Mo, Niklas Thon, Arnaud J P E Vincent, Michelle M Kim, Guido Reifenberger, Susan M Chang, Shawn L Hervey-Jumper, Mitchel S Berger, Joerg-Christian Tonn
Journal: The Lancet Oncology (2024)

Glioma resection is associated with prolonged survival, but neuro-oncological trials have frequently refrained from quantifying the extent of resection. The Response Assessment in Neuro-Oncology (RANO) resect group is an international, multidisciplinary group that aims to standardise research practice by delineating the oncological role of surgery in diffuse adult-type gliomas as defined per WHO 2021 classification. Favourable survival effects of more extensive resection unfold over months to decades depending on the molecular tumour profile. In tumours with a more aggressive natural history, supramaximal resection might correlate with additional survival benefit. Weighing the expected survival benefits of resection as dictated by molecular tumour profiles against clinical factors, including the introduction of neurological deficits, we propose an algorithm to estimate the oncological effects of surgery for newly diagnosed gliomas. The algorithm serves to select patients who might benefit most from extensive resection and to emphasise the relevance of quantifying the extent of resection in clinical trials.
Translating the theranostic concept to neuro-oncology: disrupting barriers
Authors: Nathalie L Albert, Emilie Le Rhun, Giuseppe Minniti, Maximilian J Mair, Norbert Galldiks, Nelleke Tolboom, Asgeir S Jakola, Maximilian Niyazi, Marion Smits, Antoine Verger, Francesco Cicone, Michael Weller, Matthias Preusser
Journal: The Lancet Oncology (2024)
Capivasertib and fulvestrant for patients with hormone receptor-positive, HER2-negative advanced breast cancer (CAPItello-291): patient-reported outcomes from a phase 3, randomised, double-blind, placebo-controlled trial
Authors: Mafalda Oliveira, Hope S Rugo, Sacha J Howell, Florence Dalenc, Javier Cortes, Henry L Gomez, Xichun Hu, Masakazu Toi, Komal Jhaveri, Petr Krivorotko, Sibylle Loibl, Serafin Morales Murillo, Meena Okera, Zbigniew Nowecki, Yeon Hee Park, Joo Hyuk Sohn, Eriko Tokunaga, Samih Yousef, Lyudmila Zhukova, Marta Fulford, Haylee Andrews, Ian Wadsworth, Celina D'Cruz, Nicholas C Turner
Journal: The Lancet Oncology (2024)
Defining the quality of interdisciplinary care for patients with brain metastases: modified Delphi panel recommendations
Authors: Camilo E Fadul, Jason P Sheehan, Julio Silvestre, Gloribel Bonilla, Joseph A Bovi, Manmeet Ahluwalia, Riccardo Soffietti, David Hui, Roger T Anderson
Journal: The Lancet Oncology (2024)
Effectiveness of Multilevel and Multidomain Interventions to Improve Glycemic Control in U.S. Racial and Ethnic Minority Populations: A Systematic Review and Meta-analysis
Authors: Eli M. Falk, Erin M. Staab, Amber N. Deckard, Sofia I. Uranga, Nikita C. Thomas, Wen Wan, Andrew J. Karter, Elbert S. Huang, Monica E. Peek, Neda Laiteerapong
Journal: Diabetes Care (2024)

BACKGROUND Racial and ethnic disparities in type 2 diabetes outcomes are a major public health concern. Interventions targeting multiple barriers may help address disparities. PURPOSE To conduct a systematic review and meta-analysis of diabetes self-management education (DSME) interventions in minority populations. We hypothesized that interventions addressing multiple levels (individual, interpersonal, community, and societal) and/or domains (biological, behavioral, physical/built environment, sociocultural environment, and health care system) would have the greatest effect on hyperglycemia. DATA SOURCES We performed an electronic search of research databases PubMed, Scopus, CINAHL, and PsycINFO (1985–2019). STUDY SELECTION We included randomized controlled trials of DSME interventions among U.S. adults with type 2 diabetes from racial and ethnic minority populations. DATA EXTRACTION We extracted study parameters on DSME interventions and changes in percent hemoglobin A1c (HbA1c). DATA SYNTHESIS A total of 106 randomized controlled trials were included. Twenty-five percent (n = 27) of interventions were exclusively individual-behavioral, 51% (n = 54) were multilevel, 66% (n = 70) were multidomain, and 42% (n = 45) were both multilevel and multidomain. Individual-behavioral interventions reduced HbA1c by −0.34 percentage points (95% CI −0.46, −0.22; I2 = 33%) (−3.7 [−5.0, −2.4] mmol/mol). Multilevel interventions reduced HbA1c by −0.40 percentage points (95% CI −0.51, −0.29; I2 = 68%) (−4.4 [−5.6, −3.2] mmol/mol). Multidomain interventions reduced HbA1c by −0.39 percentage points (95% CI −0.49, −0.29; I2 = 68%) (−4.3 [−5.4, −3.2] mmol/mol). Interventions that were both multilevel and multidomain reduced HbA1c by −0.43 percentage points (95% CI −0.55, −0.31; I2 = 69%) (−4.7 [−6.0, −3.4] mmol/mol). LIMITATIONS The analyses were restricted to RCTs. CONCLUSIONS Multilevel and multidomain DSME interventions had a modest impact on HbA1c. Few DSME trials have targeted the community and society levels or physical environment domain. Future research is needed to evaluate the effects of these interventions on outcomes beyond HbA1c.
Extent of Lymphadenectomy for Surgical Management of Right-Sided Colon Cancer: The Randomized Phase III RELARC Trial
Authors: Junyang Lu, Jiadi Xing, Lu Zang, Chenghai Zhang, Lai Xu, Guannan Zhang, Zirui He, Yueming Sun, Yifei Feng, Xiaohui Du, Shidong Hu, Pan Chi, Ying Huang, Ziqiang Wang, Ming Zhong, Aiwen Wu, Anlong Zhu, Fei Li, Jianmin Xu, Liang Kang, Jian Suo, Haijun Deng, Yingjiang Ye, Kefeng Ding, Tao Xu, Yuelun Zhang, Zhongtao Zhang, Minhua Zheng, Xiangqian Su, Yi Xiao, Bin Wu, Guole Lin, Huizhong Qiu, Lei Chen, Bo Feng, Dongjian Ji, Changzheng He, Ze Fu, Weizhong Jiang, Qingbin Wu, None MD, Xiangbing Deng, None MD, Minhao Yu, Yang Luo, Pengju Chen, Yunfeng Yao, Wenlong Guan, Ang Li, Feng Cao, Guodong He, Xiaowen He, Yujia Chen, Daguang Wang, Guoxin Li, Kai Shen, Jun Li, Hongwei Yao, Yingchi Yang
Journal: Journal of Clinical Oncology (2024)

PURPOSE Complete mesocolic excision (CME) is being increasingly used for the treatment of right-sided colon cancer, although there is still no strong evidence that CME provides better long-term oncological outcomes than D2 dissection. The controversy is mainly regarding the survival benefit from extended lymph node dissection emphasized by CME. METHODS This multicenter, open-label, randomized controlled trial (ClinicalTrials.gov identifier: NCT02619942 ) was performed across 17 hospitals in China. Patients diagnosed with stage T2-T4aNanyM0 or TanyN + M0 right-sided colon cancer were randomly assigned (1:1) to undergo either CME or D2 dissection during laparoscopic right colectomy. The primary outcome was the 3-year disease-free survival (DFS), and the main secondary outcome was the 3-year overall survival (OS). RESULTS Between January 11, 2016, and December 26, 2019, 1,072 patients were randomly assigned (536 patients to CME and 536 patients to D2 dissection). In total, 995 patients (median age 61 years, 59% male) were included in the primary analysis (CME [n = 495] v D2 dissection [n = 500]). No significant differences were found between the groups in 3-year DFS (hazard ratio [HR], 0.74 [95% CI, 0.54 to 1.02]; P = .06; 86.1% in the CME group v 81.9% in the D2 group) or in 3-year OS (HR, 0.70 [95% CI, 0.43 to 1.16]; P = .17; 94.7% in the CME group v 92.6% in the D2 group). CONCLUSION This trial failed to find evidence of superior DFS outcome for CME compared with standard D2 lymph node dissection in primary surgical excision of right-sided colon cancer. Standard D2 dissection should be the routine procedure for these patients. CME should only be considered in patients with obvious mesocolic lymph node involvement.
Lung water density is increased in patients at risk of heart failure and is largely independent of conventional CMR measures
Authors: Nithin R Iyer, Jennifer A Bryant, Thu-Thao Le, Justin G Grenier, Richard B Thompson, Calvin W L Chin, Martin Ugander
Journal:  (2024)

Non-invasive methods to quantify pulmonary congestion are lacking in clinical practice. Cardiovascular magnetic resonance (CMR) lung water density (LWD) mapping is accurate and reproducible and has prognostic value. However, it is not known whether LWD is associated with routinely acquired CMR parameters.
Clinical Treatment Score Post-5 Years (CTS5) and Late Recurrence Risk in Hormone Receptor–Positive, HER2-Positive Breast Cancer
Authors: Saranya Chumsri, Tanmayi Pai, Yaohua Ma, Zhuo Li, Angelica Gil, Alvaro Moreno-Aspitia, Gerardo Colon-Otero, Katherine L. Pogue-Geile, Priya Rasgoti, Soonmyung Paik, Edith A. Perez, E. Aubrey Thompson
Journal: Journal of the National Comprehensive Cancer Network (2024)

Background: The Clinical Treatment Score post-5 years (CTS5) is a risk stratification tool used to determine the risk of late recurrence in hormone receptor–positive (HR+), HER2-negative breast cancer (BC). Limited data exist on its use in HR+, HER2-positive (HER2+) BC. Patients and Methods: CTS5 was evaluated in HR+, HER2+ BC in the North Central Cancer Treatment Group (NCCTG) N9831 (Alliance) and NSABP B-31 (NRG) trials. Results: A total of 1,862 patients with HR+, HER2+ BC without recurrence 5 years after enrollment were included. Overall, the CTS5 score was significantly associated with recurrence-free survival (RFS), with a hazard ratio (HR) of 1.35 (95% CI, 1.12–1.63; P =.002), but did not reach statistical significance in patients who received trastuzumab (n=829; HR, 1.29; 95% CI, 0.98–1.71; P =.07). CTS5 risk category was not significantly associated with RFS. In patients who received trastuzumab, other variables used in CTS5, including patient age and tumor size, were not significantly associated with RFS. N3 was significantly associated with worse outcomes (HR, 1.86; 95% CI, 1.09–3.17; P =.02) compared with N0–N1. Paradoxically, higher tumor grade was associated with better outcomes after 5 years in the multivariate analysis (HR, 0.71; 95% CI, 0.50–1.00; P =.05). The incidence of recurrences or deaths between years 5 to 10 was 10.6% in the CTS5 low-risk category, 5.6% in the intermediate-risk category, and 9.8% in the high-risk category. Conclusions: The CTS5 model does not accurately predict the risk of late recurrence in HR+, HER2+ BC treated with adjuvant trastuzumab in the N9831 and B-31 trials. This study underlines the need to develop a new prognostic model to better delineate the risk of late recurrence in patients with HR+, HER2+ BC receiving adjuvant trastuzumab. ClinicalTrials.gov identifiers: NCT00005970 (NCCTG N9831) and NCT00004067 (NRG/NSABP B-31).
Life’s Essential 8 and Incident Cardiovascular Disease in U.S. Women With Breast Cancer
Authors: Elena Wadden, Alexi Vasbinder, Vidhushei Yogeswaran, Aladdin H Shadyab, Nazmus Saquib, Yangbo Sun, Lisa Warsinger Martin, Ramesh Mazhari, JoAnn E Manson, Marcia Stefanick, Ana Barac, Michael S Simon, Kerryn Reding, Richard K Cheng
Journal: JACC CardioOncology (2024)

Relationships between lifestyle risk factors and cardiovascular disease (CVD) risk in women with breast cancer (BC) are underexplored.
Preventing Cardiac Damage in Patients Treated for Breast Cancer and Lymphoma
Authors: David Austin, Rebecca H Maier, Nasima Akhter, Mohammad Sayari, Emmanuel Ogundimu, Jamie M Maddox, Sharareh Vahabi, Alison C Humphreys, Janine Graham, Helen Oxenham, Sophie Haney, Nicola Cresti, Mark Verrill, Wendy Osborne, Kathryn L Wright, Rebecca Goranova, James R Bailey, Nagesh Kalakonda, Mac Macheta, Mari F Kilner, Moya E Young, Nick J Morley, Pratap Neelakantan, Georgia Gilbert, Byju K Thomas, Richard J Graham, Takeshi Fujisawa, Nicholas L Mills, Victoria Hildreth, Jonathan Prichard, Adetayo S Kasim, Helen C Hancock, Chris Plummer
Journal: JACC CardioOncology (2024)

BACKGROUND Cardiotoxicity is a concern for cancer survivors undergoing anthracycline chemotherapy.Enalapril has been explored for its potential to mitigate cardiotoxicity in cancer patients.The dose-dependent cardiotoxicity effects of anthracyclines can be detected early through the biomarker cardiac troponin. OBJECTIVESThe PROACT (Preventing Cardiac Damage in Patients Treated for Breast Cancer and Lymphoma) clinical trial assessed the effectiveness of enalapril in preventing cardiotoxicity, manifesting as myocardial injury and cardiac function impairment, in patients undergoing high-dose anthracycline-based chemotherapy for breast cancer or non-Hodgkin lymphoma.METHODS This prospective, multicenter, open-label, randomized controlled trial employed a superiority design with observer-blinded endpoints.A total of 111 participants, scheduled for 6 cycles of chemotherapy with a planned dose of $300 mg/m 2 doxorubicin equivalents, were randomized to receive either enalapril (titrated up to 20 mg daily) or standard care without enalapril.RESULTS Myocardial injury, indicated by cardiac troponin T ($14 ng/L), during and 1 month after chemotherapy, was observed in 42 (77.8%) of 54 patients in the enalapril group vs 45 (83.3%) of 54 patients in the standard care group (OR: 0.65; 95% CI: 0.23-1.78).Injury detected by cardiac troponin I (>26.2ng/L) occurred in 25 (47.2%) of 53 patients on enalapril compared with 24 (45.3%) of 53 in standard care (OR: 1.10; 95% CI: 0.50-2.38).A relative decline of more than 15% from baseline in left ventricular global longitudinal strain was observed in 10 (21.3%) of 47 patients on enalapril and 9 (21.9%) of 41 in standard care (OR: 0.95; 95% CI: 0.33-2.74).An absolute decline of >10% to <50% in left ventricular ejection fraction was seen in 2 (4.1%) of 49 patients on enalapril vs none in patients in standard care. CONCLUSIONSAdding enalapril to standard care during chemotherapy did not prevent cardiotoxicity in patients receiving high-dose anthracycline-based chemotherapy.(PROACT: Can we prevent Chemotherapy-related Heart Damage in Patients With Breast Cancer and Lymphoma?; NCT03265574) (JACC CardioOncol.
Letter to the Editor: Can pFIB scores reliably exclude significant liver fibrosis in pediatric MASLD?
Authors: Yusuf Yilmaz
Journal: Hepatology (2024)

1Department of Gastroenterology, School of Medicine, Recep Tayyip Erdoğan University, Rize, Türkiye 2The Global NASH Council, Washington, DC, USA Correspondence Yusuf Yilmaz, Recep Tayyip Erdoğan Üniversitesi Rektörlüğü, Rize, Türkiye. Email: [email protected]
Can pFIB scores reliably exclude significant liver fibrosis in pediatric MASLD?
Authors: Sander Lefere, Antonella Mosca, Christian Hudert, Ellen Dupont, Emer Fitzpatrick, Eirini Kyrana, Anil Dhawan, Laura Kalveram, Andrea Pietrobattista, Anja Geerts, Ruth De Bruyne
Journal: Hepatology (2024)

Lefere, Sander; Mosca, Antonella; Hudert, Christian; Dupont, Ellen; Fitzpatrick, Emer; Kyrana, Eirini; Dhawan, Anil; Kalveram, Laura; Pietrobattista, Andrea; Geerts, Anja; De Bruyne, Ruth Author Information